Precision Biosciences (DTIL) Accounts Payables (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Accounts Payables of $944000.0 for Q1 2026, up 2.16% year-over-year from $924000.0 in Q1 2025, and up 218.92% quarter-over-quarter from $296000.0 in Q4 2025.
Precision Biosciences (DTIL) Accounts Payables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Accounts Payables for 9 consecutive years, with $944000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 2.16% year-over-year to $944000.0; the TTM figure through Mar 2026 stood at $944000.0 (up 2.16% YoY), while the FY2025 annual figure was $296000.0, down 77.44% from the prior year.
- Accounts Payables improved to $944000.0 in Q1 2026 per DTIL's latest filing, from $296000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $3.0 million in Q4 2023 and bottomed at $296000.0 in Q4 2025.
- Historically, Accounts Payables has averaged $1.0 million across 5 years, with a median of $944000.0 in 2026.
- Annual changes were most pronounced in 2023 — Accounts Payables soared 354.52% — and 2025, when it plunged 77.44%.
- Precision Biosciences' Accounts Payables stood at $653000.0 in 2022, then surged by 354.52% to $3.0 million in 2023, then sank by 55.8% to $1.3 million in 2024, then slumped by 77.44% to $296000.0 in 2025, then soared by 218.92% to $944000.0 in 2026.
- Business Quant data shows DTIL's Accounts Payables at $944000.0 in Q1 2026, $296000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 828,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 828,000.00 |
| Mar 31, 2026 | 944,000.00 |
| Dec 31, 2025 | 296,000.00 |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 924,000.00 |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 958,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Sep 30, 2023 | 531,000.00 |
| Jun 30, 2023 | 781,000.00 |
| Mar 31, 2023 | 701,000.00 |
| Dec 31, 2022 | 653,000.00 |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 797,000.00 |
| Mar 31, 2022 | 699,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 486,000.00 |